VIR Stock Overview
An immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vir Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.39 |
| 52 Week High | US$27.48 |
| 52 Week Low | US$7.61 |
| Beta | 0.46 |
| 1 Month Change | 18.88% |
| 3 Month Change | -7.56% |
| 1 Year Change | -61.93% |
| 3 Year Change | -76.88% |
| 5 Year Change | n/a |
| Change since IPO | -25.89% |
Recent News & Updates
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates
May 05
Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 03Recent updates
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates
May 05Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 03Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Feb 28Sticking With Vir Biotechnology
Jan 17Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%
Aug 07Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive
Jul 24Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically
Feb 28Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 07Vir Biotechnology: Focus On Hepatitis B Development Could End Up Paying Off
Oct 12Vir Biotech gains 12% as U.S. govt. inks multi-year deal worth up to $1B
Oct 04Vir begins dosing in mid-stage study of VIR-2218, VIR-3434 for hepatitis D virus
Sep 22Vir Biotechnology falls 15% on Q2 revenue miss impacted by ~$400M for potential write-offs
Aug 09Vir: Biotechnology's Best Near-Term Capital Gain Prospect
Jul 27Shareholder Returns
| VIR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | -1.2% | -1.2% |
| 1Y | -61.9% | 4.7% | 21.5% |
Return vs Industry: VIR underperformed the US Biotechs industry which returned 4.6% over the past year.
Return vs Market: VIR underperformed the US Market which returned 25.2% over the past year.
Price Volatility
| VIR volatility | |
|---|---|
| VIR Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VIR's share price has been volatile over the past 3 months.
Volatility Over Time: VIR's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 587 | Marianne De Backer | www.vir.bio |
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Vir Biotechnology, Inc. Fundamentals Summary
| VIR fundamental statistics | |
|---|---|
| Market cap | US$1.41b |
| Earnings (TTM) | -US$539.44m |
| Revenue (TTM) | US$79.60m |
17.8x
P/S Ratio-2.6x
P/E RatioIs VIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIR income statement (TTM) | |
|---|---|
| Revenue | US$79.60m |
| Cost of Revenue | US$507.81m |
| Gross Profit | -US$428.21m |
| Other Expenses | US$111.22m |
| Earnings | -US$539.44m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.96 |
| Gross Margin | -537.97% |
| Net Profit Margin | -677.69% |
| Debt/Equity Ratio | 0% |
How did VIR perform over the long term?
See historical performance and comparison